Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Jace who wrote (1379)	8/28/1998 9:58:00 AM
From: Zvi Yammer	Respond to of 2742

Jace; How dare you inject a dosage of reality into our adjuvant fantasy.!!! anyway you did make some good points and welcome to the board. Welcome to Christina as well, Zvi

To: Jace who wrote (1379)	9/1/1998 5:31:00 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 2742

<<All Cistron has is a POTENTIAL adjuvant. They have only results in rats that we know of. There are a lot of other adjuvants out there.>> These are good points/concerns. Cistron's most recent IL-1b adjuvant studies with a flu vaccine supposedly involved animals other than rats. These results haven't been released publicly, but I suspect they'll be published and/or presented this fall similar to last year's results. Since Cistron was able to attract a partner as renowned as Pasteur Merieux Connaught, I'm assuming Cistron's current data supports the strongly positive data we saw last year. Yup, there's good competition for vaccine adjuvants as shown by any number of posts on this thread, and vaccine technology is certainly a hot field. Fortunately, there's also quite a bit of independent research showing that IL-1b is potentially an effective adjuvant/immunostimulator for both infectious disease and cancer applications. I've listed several representative abstracts below. <<A cytokine as an adjuvant without side effects is incredible! This whole thing will be dumped in a minute if side effects show up later.>> The IL-1b safety issue has been addressed over the years. The following abstract seems to be one of the standard references describing a "safe" and active IL-1b fragment known as 163-171: Vaccine 1993;11(5):594-595 Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide 163-171. Tagliabue A, Boraschi D ncbi.nlm.nih.gov ---- I just found a current abstract describing analogs of 163-171: Immunopharmacology 1998 Jan;38(3):237-245 Immunomodulating activity of analogs of noninflammatory fragment 163-171 of human interleukin-1beta. Bajpai K, Singh VK, Sharan R, Yadav VS, Haq W, Mathur KB, Agarwal SS ncbi.nlm.nih.gov --- <<Why do you expect so much from IL1?>> Because of Cistron research with a flu vaccine and independent research involving IL-1b in cancer vaccines delivered both as an adjuvant and using DNA techniques. Here are a few more representative abstracts: J Immunol 1996 Dec 15;157(12):5503-5511 A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. Hakim I, Levy S, Levy R ncbi.nlm.nih.gov ---- Vaccine 1997 Oct;15(15):1687-1696 DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Maecker HT, Umetsu DT, DeKruyff RH, Levy S ncbi.nlm.nih.gov ---- Cancer Res 1990 Feb 15;50(4):1212-1215 Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. McCune CS, Marquis DM ncbi.nlm.nih.gov ---- Most importantly from a Cistron investment perspective (i.e., to the best of my knowledge - please verify), Cistron has rights to these IL-1b fragments and applications. Rudy